Arias Fernando, Zarandona Uxúe, Ibáñez-Beróiz Berta, Ibáñez Reyes, Campo Maider, Cacicedo Jon, García-Rueda Noelia, Baztán Beatriz, Villanueva Raquel, Fresán Marta, Redín Iñaki, Osés Ana T, Hurtado Victoria, Villafranca Inés, Iancu Vasti, Almeida Pilar, Moreno Nieves, Cadena Soraya, Carruesco Irene, Allegue Marián, González Ana B
Radiation Oncology Department, University Hospital of Navarre, Irunlarrea 3, Pamplona, Spain.
University Hospital Miguel Servet, Saragossa, Spain.
Clin Transl Oncol. 2025 Feb;27(2):778-784. doi: 10.1007/s12094-024-03603-4. Epub 2024 Jul 30.
Pain in cancer patients has enormous impact on their quality-of-life. Radiation therapy (RT) is a cornerstone in cancer treatment. The objective of the PREDORT study is to estimate the prevalence of pain in patients attending at Radiation Oncology (RO) Services.
A prospective, multicenter study was designed for patients treated at the RO Services of reference hospitals. Patients were seen in their initial Nursing consultation, during which key data was collected, including demographic and comorbidities data, medical history, and oncological and pain characteristics. The study has received approval from the Ethics Committee of Navarra, and all patients signed the Informed Consent.
Of the 860 participating patients, 306 reported some type of pain, which implies a prevalence of 35.6%. Of them, 213 identified a cause of oncological origin. The proportion of pain was similar among sexes, but the proportion of non-cancer pain was higher among women (p < 0.05). Regarding pain intensity, the magnitude of breakthrough pain in patients with oncological pain is nearly 1 point greater than in patients with non-oncological pain (7.53 vs 6.81; p = 0.064). Cancer pain is more likely to be limiting of normal life than non-cancer pain (59% versus 38%, p < 0.001). Regarding analgesic treatment, only 60/306 patients (19.6%) were receiving strong opioids. There were 68 patients with pain without any treatment (22.2%).
The prevalence of pain in cancer patients referred to RO services is 35.6%, with the prevalence of exclusively oncological pain being 24.8%. Understanding and addressing oncological pain is essential to provide comprehensive care to patients.
癌症患者的疼痛对其生活质量有巨大影响。放射治疗(RT)是癌症治疗的基石。PREDORT研究的目的是估计在放射肿瘤学(RO)服务机构就诊的患者中疼痛的患病率。
针对参考医院RO服务机构治疗的患者设计了一项前瞻性多中心研究。患者在首次护理咨询时接受检查,在此期间收集关键数据,包括人口统计学和合并症数据、病史以及肿瘤学和疼痛特征。该研究已获得纳瓦拉伦理委员会的批准,所有患者均签署了知情同意书。
在860名参与研究的患者中,306人报告有某种类型的疼痛,这意味着患病率为35.6%。其中,213人确定疼痛原因是肿瘤源性。疼痛比例在性别之间相似,但非癌性疼痛比例在女性中更高(p < 0.05)。关于疼痛强度,肿瘤性疼痛患者的爆发性疼痛程度比非肿瘤性疼痛患者高近1分(7.53对6.81;p = 0.064)。癌症疼痛比非癌症疼痛更有可能限制正常生活(59%对38%,p < 0.001)。关于镇痛治疗,只有60/306名患者(19.6%)正在接受强阿片类药物治疗。有68名疼痛患者未接受任何治疗(22.2%)。
转诊至RO服务机构的癌症患者中疼痛患病率为35.6%,仅肿瘤性疼痛的患病率为24.8%。了解和处理肿瘤性疼痛对于为患者提供全面护理至关重要。